Mega Contracts Monitor ($100M+) — March 08, 2026

Two contracts totaling $2.37B obligated ($8.42B potential) to Savannah River Mission Completion underscore DOE's multi-billion push for Savannah River site liquid waste and tank closure through 2031.

$2.05B across Oracle and Amgen for VA EHRM hosting to 2026 and HHS thrombocytopenia R&D to 2032, with $712M already outlayed in Amgen, affirm federal healthcare pipeline funding.

$1.44B GSA award for software life cycle to 2025 highlights repeatable defense R&D demand, with $2.9B ceiling via options.

Zero or negative outlays in 50% of contracts (Oracle $0, SAIC -$175K, GardaWorld $0) signal potential delays despite high obligations.

Firm fixed price terms in 50% of awards (Oracle, Amgen, GardaWorld) expose to cost inflation over 8-10 year horizons.

Long durations to 2031-2032 (67% of value) vulnerable to budget shifts in DOE/HHS.

$7.8B+ in unobligated options across all contracts, led by SRMC's $5.3B+$0.76B DOE upside.

Recurring full/open competition wins for non-small businesses in remediation, defense, and health position incumbents for follow-ons.

38% of value ($2.37B) in two SRMC awards for Savannah River waste/tank ops to 2031 highlights sustained nuclear cleanup spend.

33% of value ($2.05B) in VA/HHS IT and biotech R&D through 2026-2032 with high outlays signals embedded healthcare modernization.

{"entity"=>"Savannah River Mission Completion, LLC", "reason"=>"Dominates 40% of period value with $8.4B potential in DOE remediation.", "trigger"=>"Option funding >$1B or contract extensions"}

{"entity"=>"SAIC", "reason"=>"Largest non-DOE award ($1.44B) with subaward dependencies and 2025 expiry.", "trigger"=>"Follow-on GSA defense R&D awards"}

{"entity"=>"DOE Savannah River Budget", "reason"=>"Underpins 38% of value; shifts could cascade to SRMC.", "trigger"=>"FY2027 appropriations variance >10%"}